<!DOCTYPE html>
<html lang="en">
<head>
        <meta charset="utf-8" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />
        <meta name="generator" content="Pelican" />
        <title>Oramed Pharma ($ORMD) — great medical innovation, or just great stock promotion?</title>
        <link rel="stylesheet" href="https://www.stevehemingway.com/theme/css/main.css" />
        <link href="https://www.stevehemingway.com/feeds/all.atom.xml" type="application/atom+xml" rel="alternate" title="Postcards from the Internet Atom Feed" />
        <link href="https://www.stevehemingway.com/feeds/all.rss.xml" type="application/rss+xml" rel="alternate" title="Postcards from the Internet RSS Feed" />
        <meta name="description" content="28 Nov The Parallax View published a 9,933-word report on Oramed Pharmaceuticals (NASDAQ: ORMP on), an oral drug delivery systems company focused..." />
</head>

<body id="index" class="home">
        <header id="banner" class="body">
                <h1><a href="https://www.stevehemingway.com/">Postcards from the Internet <strong>Life, the universe, and the markets</strong></a></h1>
                <nav><ul>
                    <li><a href="https://www.stevehemingway.com/pages/newsletter.html">Newsletter</a></li>
                    <li><a href="https://www.stevehemingway.com/pages/about.html">About</a></li>
                    <li><a href="https://www.stevehemingway.com/category/knebworth.html">Knebworth</a></li>
                    <li class="active"><a href="https://www.stevehemingway.com/category/markets.html">markets</a></li>
                    <li><a href="https://www.stevehemingway.com/category/misc.html">misc</a></li>
                    <li><a href="https://www.stevehemingway.com/category/trading.html">trading</a></li>
                </ul></nav>
        </header><!-- /#banner -->
<section id="content" class="body">
  <article>
    <header>
      <h1 class="entry-title">
        <a href="https://www.stevehemingway.com/oramed-pharma-ormd-great-medical-innovation-or-just-great-stock-promotion.html" rel="bookmark"
           title="Permalink to Oramed Pharma ($ORMD) — great medical innovation, or just great stock promotion?">Oramed Pharma ($<span class="caps">ORMD</span>) &#8212; great medical innovation, or just great stock&nbsp;promotion?</a></h1>
    </header>

    <div class="entry-content">
<footer class="post-info">
        <abbr class="published" title="2021-11-28T00:00:00+00:00">
                Published: Sun 28 November 2021
        </abbr>
		<br />
        <abbr class="modified" title="2021-12-03T13:24:15.501234+00:00">
                Updated: Fri 03 December 2021
        </abbr>

        <address class="vcard author">
                By                         <a class="url fn" href="https://www.stevehemingway.com/author/me.html">me</a>
        </address>
<p>In <a href="https://www.stevehemingway.com/category/markets.html">markets</a>.</p>

</footer><!-- /.post-info -->      <h1>28&nbsp;Nov</h1>
<p>The Parallax View published a 9,933-word report on Oramed Pharmaceuticals (<span class="caps">NASDAQ</span>: <span class="caps">ORMP</span> on), an oral drug delivery systems company focused on treating diabetes. Parallax highlighted excessive insider compensation including $3.2 million to the company <span class="caps">CEO</span>, Nadav Kidron, and his mother, who serves as Chief Scientific Officer. In addition, Parallax noted that the company spends only ~1% of its market cap on research and development and highlighted litigation around stock grants and a Chinese partner. Parallax also alleged the company research Oramed stock fell 26% this past week but remains up roughly 360% this year. Follow Parallax on Twitter @ParallaxBio and join their newsletter&nbsp;here.</p>
    </div><!-- /.entry-content -->

  </article>
</section>
        <section id="extras" class="body">
                <div class="social">
                        <h2>social</h2>
                        <ul>
                            <li><a href="https://www.stevehemingway.com/feeds/all.atom.xml" type="application/atom+xml" rel="alternate">atom feed</a></li>
                            <li><a href="https://www.stevehemingway.com/feeds/all.rss.xml" type="application/rss+xml" rel="alternate">rss feed</a></li>

                        </ul>
                </div><!-- /.social -->
        </section><!-- /#extras -->

        <footer id="contentinfo" class="body">
                <address id="about" class="vcard body">
                Proudly powered by <a href="https://getpelican.com/">Pelican</a>, which takes great advantage of <a href="https://www.python.org/">Python</a>.
                </address><!-- /#about -->

                <p>The theme is by <a href="https://www.smashingmagazine.com/2009/08/designing-a-html-5-layout-from-scratch/">Smashing Magazine</a>, thanks!</p>
        </footer><!-- /#contentinfo -->

</body>
</html>